Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib and Everolimus in c-kit+ AML
NCT00762632Phase 2Completed
- Sponsor
- Technical University of Munich
- Start
- Dec 2007
- Primary completion
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nilotinib, everolimus in acute myeloid leukemia (AML), sponsored by Technical University of Munich. Started Dec 2007; status: completed.
02
Drugs
nilotinibeverolimus
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00762632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00762632.